Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial by Lam, Carolyn S. P. et al.
571
Epidemiological studies have revealed striking sex-related differences in clinical presentation,1–5 risk factors,6,7 and 
prognosis8–10 of heart failure (HF). One of the most notable 
sex-related differences in HF is that most women have HF 
with preserved ejection fraction (HFPEF), an important dis-
order that is incompletely understood.11
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Previous studies have been limited by retrospective design,12 
underrepresentation of women, or exclusion of HFPEF.13 
Three previous trials (DIG-PEF [Digitalis Intervention 
Group-Preserved Ejection Fraction],14 CHARM-Preserved 
[Candesartan in Heart failure: Assessment of Reduction 
in Mortality and morbidity: Preserved Ejection fraction],15 
Pep-CHF [Perindopril in Elderly People with Chronic Heart 
Failure]16) have included sizeable numbers of patients with 
HFPEF but have been criticized for selecting patients who 
were not necessarily representative of patients with HFPEF 
seen in population-based studies.17 The Irbesartan in Heart 
Failure with Preserved Ejection Fraction (I-PRESERVE) trial18 
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of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms.
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baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline 
characteristics seemed to moderate this finding.
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is the largest HFPEF trial to date and included patients (60% 
women) who closely resembled those with typical HFPEF as 
described in population-based epidemiological studies.1,2
Elucidating the effect of sex and risk factors on outcomes 
in HFPEF may advance fundamental understanding of the 
HFPEF syndrome and guide the design of tailored inter-
vention strategies. Recognizing that a substantial proportion 
of events during follow-up in the I-PRESERVE trial were 
noncardiovascular events,19 in sharp contrast to the profile of 
events observed in HF studies of predominantly younger men, 
we hypothesized that women with HFPEF would be older and 
would have more noncardiovascular comorbidities at baseline 
compared with men, which could predispose to sex-related 
differences in outcomes in HFPEF. Accordingly, we aimed to 
test this hypothesis by examining the differences in clinical 
characteristics and prognosis in women and men with HFPEF 
from the large, prospective I-PRESERVE trial.
Methods
Sample
The study sample consisted of the 4128 patients enrolled in the 
I-PRESERVE trial.18 Inclusion criteria included age ≥60 years old, 
clinical signs and symptoms of HF, and a left ventricular ejection 
fraction ≥45%. The intervention was irbesartan 300 mg/day versus 
placebo. Although the primary trial results,18 mode of death,19 and HF-
related quality of life20 have been previously published, where some 
results were stratified by sex and heterogeneity in the treatment effect 
by sex was not found, the detailed sex-specific analyses and hospital-
ization events presented here have not been previously reported.
Outcomes
The primary outcome of I-PRESERVE was a composite of all-cause 
death or the first hospitalization for a protocol-specified adjudicated 
cardiovascular hospitalization (defined as worsening HF, unstable angi-
na, myocardial infarction, ventricular arrhythmia, atrial arrhythmia, or 
stroke). Secondary outcomes included cardiovascular death, all-cause 
mortality, HF mortality or hospitalization, and change in quality of life 
related to HF, New York Heart Association (NYHA) functional class, 
and N-terminal pro-B-type natriuretic peptide level in blood (Roche 
Elecsys assay). Outcomes (deaths and hospitalizations) were adjudicat-
ed by an independent Clinical Endpoint Committee using prespecified 
criteria that have been previously published.19 HF mortality was de-
fined as death because of worsening or intractable HF, whereas HF hos-
pitalization was defined as one with a primary diagnosis of worsening 
HF, where patients with worsening HF displayed symptoms and signs 
of HF, as well as diagnostic evidence, such as a significant increase 
in natriuretic peptides, radiographic congestion, or prerenal azotemia.
Statistical Analysis
Baseline variables were compared between men and women using 
2-sided Student t tests or Wilcoxon rank-sum tests for continuous 
variables and Fisher exact tests or χ2 tests for categorical variables. 
For each outcome of interest, time to first event was recorded, where-
as other events were censored. Cox proportional hazards analysis 
was used to model the effect of sex, baseline covariates (age, obesity, 
NHYA status, HF cause, HF hospitalization 6 months before base-
line, history of hypertension, stable angina pectoris, myocardial in-
farction, percutaneous coronary intervention/coronary artery bypass 
surgery, atrial fibrillation, diabetes mellitus, stroke/transient ischemic 
attack, chronic obstructive pulmonary disease/asthma, valve disease, 
smoking, ejection fraction, heart rate, systolic blood pressure, hemo-
globin, N-terminal pro-B-type natriuretic peptide, neutrophil count, 
glomerular filtration rate, and medications), as well as the interac-
tions between sex and each baseline covariate. The analyses of inter-
actions with sex focused on all-cause events because the results for 
cardiovascular and noncardiovascular events were similar, there were 
more all-cause events, and competing risks are incorporated into the 
end point. To help account for multiple comparisons, the threshold for 
statistical significance was P<0.01. Estimated P values are presented 
for readers who would like to make further adjustments, considering 
the number of tests done to compare women and men.
Results
Baseline Characteristics
Among 4128 elderly patients with HFPEF, 2491 (60%) were 
women, who were, on average, 1 year older than men (Table 1). 
Compared with men, women were more likely to be obese and 
have a history of hypertension; were less likely to have an isch-
emic cause, stable angina pectoris, previous myocardial infarc-
tion, atrial fibrillation, chronic obstructive pulmonary disease, 
or smoking; and had a similar prevalence of diabetes mellitus. At 
baseline, heart rate was higher and peripheral edema was more 
prevalent in women compared with men. HF-specific quality 
of life was worse in women compared with men. Women were 
more likely than men to have chronic kidney disease but less 
likely to be anemic (using differential hemoglobin cut points) 
and had lower N-terminal pro-B-type natriuretic peptide levels.
Association Between Sex and Outcomes
In time-to-first event (death or hospitalization) analyses, there 
were 2430 all-cause events during a mean follow-up of 49.5 
months, of which 1754 were of cardiovascular causes (Table 2; 
Figure 1). Women had a 21% lower unadjusted risk of all-cause 
events than men, which persisted after adjusting for the differ-
ences in baseline characteristics. As with all-cause events, the 
unadjusted risk of the primary outcome of I- PRESERVE (all-
cause death or hospitalization for protocol-specified cardiovas-
cular causes) was 28% lower in women than men, remaining 
significant (albeit attenuated) after adjusting for baseline 
covariates. Similarly, in women compared with men, the unad-
justed risk of cardiovascular events alone was 25% lower, and 
the unadjusted risk of noncardiovascular events was 19% lower, 
with the difference remaining significant even after adjusting 
for baseline covariates. There was a trend for lower risk of HF-
specific events in women than men who did not reach statistical 
significance. For all-cause mortality, there were a total of 881 
deaths (447 [17.9%] in women, 434 [26.5%] in men; unad-
justed hazards ratio, 0.64; 95% CI, 0.56–0.73).
Table 3 shows the total events in women and men. In both 
women and men with HFPEF, there were more deaths from 
cardiovascular than noncardiovascular causes, with the most 
common cardiovascular cause of death being sudden death. 
Noncardiovascular causes comprised 29.1% of all deaths in 
women and 31.8% of all deaths in men. There were a total 
of 5776 all-cause hospitalizations (including repeat admis-
sions; 3239 in women and 2537 in men). In both women 
and men, there were more hospitalizations for cardiovascu-
lar than noncardiovascular causes, with the most common 
cardiovascular cause of hospitalization being worsening HF. 
Noncardiovascular causes comprised 45.1% of hospitaliza-
tions in women and 44.5% of hospitalizations in men. The risk 
ratio for overall hospitalizations in women versus men was 
0.80 (95% CI, 0.76–0.84). For cardiovascular and noncardio-
vascular hospitalizations, risk was similarly lower in women, 
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Table 1. Baseline Clinical Characteristics by Sex
Characteristic Women (n=2491) Men (n=1637) P  Value
Clinical
 Age, y 72±7 71±7 <0.001
 Body mass index, kg/m2 30±6 29±5 <0.001
 Obesity*, % 46 35 <0.001
 Heart failure cause, % ischemic 19 34 <0.001
 Stable angina pectoris, % 38 43 <0.001
 Myocardial infarction, % 17 33 <0.001
 PCI/CABG, % 9 20 <0.001
 Hypertension, % 91 85 <0.001
 Atrial fibrillation, % 27 33 <0.001
 Diabetes mellitus, % 28 27 0.74
 Chronic obstructive pulmonary disease, % 8 13 <0.001
 Smoking, % 9 32 <0.001
 NYHA class II/III/IV, % 20/77/2 22/75/3 0.006
 Hospitalization in the last 6 mo, % 44 45 0.49
 Ejection fraction, % 61±9 58±9 <0.001
Physical examination
 Heart rate, bpm 72±11 71±10 0.003
 Systolic blood pressure, mm Hg 137±15 136±15 0.14
 Diastolic blood pressure, mm Hg 79±9 79±9 0.80
 S3 gallop, number, % 8 9 0.10
 Jugular venous distension, % 7 10 0.008
 Hepatomegaly, % 17 20 0.16
 Edema, % 25 21 0.002
 Rales, % 25 24 0.43
Quality of life
 Minnesota living with heart failure score 45±21 39±21 <0.001
Investigations
 Radiological pulmonary congestion, % 42 40 0.001
 Median (Q1–Q3) NT-pro-BNP, pg/mL 301 (126–897) 413 (155–1051) <0.001
 Hemoglobin, g/dL 13.5±1.8 14.5±1.9 <0.001
 Anemia†, % 11 16 <0.001
 Estimated glomerular filtration rate, mL/min per 1.73 m2 70.8±22.1 75.2±22.9 <0.001
 Chronic kidney disease‡, % 34 26 <0.001
 Potassium, μmol/L 4.4±0.5 4.5±0.5 0.10
Medications
 Loop diuretic, % 51 53 0.08
 Thiazide diuretic, % 41 34 <0.001
 Spironolactone, % 15 17 0.08
 Angiotensin-converting enzyme inhibitor, % 23 29 <0.001
 Digoxin, % 12 16 0.006
 β-Blocker, % 59 59 0.93
 Antiarrythmic, % 8 11 0.003
 Calcium channel blocker, % 42 37 <0.001
 Nitrate, % 25 30 <0.001
 Oral anticoagulant, % 55 64 <0.001
 Aspirin, % 52 59 <0.001
 Lipid lowering, % 28 35 <0.001
PCI/CABG indicates percutaneous coronary intervention/coronary artery bypass surgery; NYHA, New York Heart Association; bpm, beats per minute; NT-pro-BNP, 
N-terminal pro-B-type natriuretic peptide.
Data are mean±SD.
*Obesity defined as body mass index ≥30 kg/m2.
†Anemia defined as hemoglobin ≤13 g/dL in men and ≤12 g/dL in women.
‡Chronic kidney disease defined as estimated glomerular filtration rate <60 mL/min per 1.73 m2.
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with risk ratios of 0.81 (0.75–0.87) and 0.78 (0.73–0.86), 
respectively. Virtually, all hospitalization subcategories were 
also lower in women than men.
Sex Differences in the Predictors of  
All-Cause Events
In sex-stratified multivariable analyses, including all base-
line covariates, variables associated with all-cause events 
in both men and women included higher age, HF hospital-
ization within 6 months, history of chronic obstructive pul-
monary disease, lower hemoglobin, and higher N-terminal 
pro-B-type natriuretic peptide (Table 4). In women, obesity, 
diabetes mellitus, lower glomerular filtration rate, and anti-
arrythmic medications were also significantly associated 
with higher risk of all-cause events. In men, higher NYHA 
status (class III/IV versus I/II), a history of coronary revas-
cularization, higher neutrophil count, and smoking were 
also significantly associated with higher risk of all-cause 
events.
To gain further insights into the hazards ratio for all-cause 
events in women relative to men, we tested for interactions 
between sex and baseline variables. There were significant 
interactions between sex and 4 baseline characteristics: stable 
angina pectoris, atrial fibrillation, NYHA class, and estimated 
glomerular filtration rate (Table 4 last column). The effect of 
each interaction, analyzed one at a time, is shown in Figure 2A. 
The risk of all-cause events was not lower in women in the 
presence of atrial fibrillation or renal dysfunction and in the 
absence of advanced NYHA class III/IV symptoms or stable 
angina pectoris. To show how the women-to-men all-cause 
hazards ratios varied with all 4 interacting variables, we entered 
different values of the interacting variables into the estimated 
Cox regression model as shown in Figure 2B. There was also a 
significant interaction between sex and antiarrythmic medica-
tions, but numbers were too small for further analyses.
Discussion
In this large sample of women and men with HFPEF, there 
were notable sex-related differences in baseline risk factors. 
Women were more likely to be obese and have a history of 
hypertension or renal impairment and were only ≈1 year older 
than men. Men were more likely to have an ischemic cause 
for HFPEF, atrial fibrillation, chronic obstructive pulmonary 
disease, and anemia. Even accounting for these baseline dif-
ferences, women with HFPEF were ≈20% less likely than 
men to experience death or hospitalization of any cause during 
follow-up. A lower risk was observed in women for both car-
diovascular and noncardiovascular events. This lower relative 
risk for women could not be explained by adjustment for dif-
ferences in baseline characteristics. However, the sex-related 
Table 2. Association Between Sex and Time to First Outcomes
Outcome
No. of Events
Event Rate Per 
100 Patient-Years Univariable Analysis Multivariable Analysis*
All Patients Women Men Women Men
HR (95% CI), 
Women vs Men P Value
HR (95% CI), 
Women vs Men P Value
All-cause death 881 447 434 4.32 6.72 0.64 (0.56–0.73) <0.001 0.70 (0.59–0.83) <0.001
All-cause hospitalization or death 2430 1382 1049 19.42 25.05 0.79 (0.73–0.86) <0.001 0.80 (0.72–0.89) <0.001
Cardiovascular hospitalization or death 1754 970 784 11.76 15.97 0.75 (0.68–0.83) <0.001 0.81 (0.72–0.92) 0.001
Noncardiovascular hospitalization or death 1483 846 638 9.89 12.40 0.81 (0.72–0.89) <0.001 0.78 (0.69–0.90) <0.001
Heart failure hospitalization or death 716 420 296 4.43 5.02 0.89 (0.77–1.04) 0.140 0.94 (0.77–1.14) 0.51
First all-cause hospitalization 2278 1314 964 18.43 23.14 0.82 (0.75–0.88) <0.001 0.77 (0.66–0.89) <0.001
HR indicates hazards ratio; HF, heart failure; PCI/CABG, percutaneous coronary intervention/coronary artery bypass surgery; TIA, transient ischemic attack; COPD, 
chronic obstructive pulmonary disease; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide.
*Adjusted for age, obesity, New York Heart Association status, HF cause, HF hospitalization within 6 mo, comorbidities/risk factors (history of hypertension, stable 
angina, myocardial infarction, PCI/CABG, atrial fibrillation, diabetes, stroke/TIA, COPD/asthma, valve disease, smoking), ejection fraction capped at 60%, heart rate, 
systolic blood pressure, hemoglobin, ln-NT-pro-BNP, natural log-neutrophil count, glomerular filtration rate capped at 90 mL/min per 1.73 m2, and all medications.
†Death from any cause or hospitalization for protocol-specified cardiovascular cause (HF, myocardial infarction, arrhythmia, or stroke).
Figure 1. Association between sex and time to first event. Haz-
ard ratios (HRs) for women versus men for first events, where HR 
<1 indicates lower risk in women. Event categories include the 
following: all cause (all-cause death or hospitalization); I-PRE-
SERVE (the primary outcome of the Irbesartan in Heart Failure 
with Preserved Ejection Fraction trial, which was all-cause death 
or hospitalization for protocol-specified cardiovascular cause, 
including heart failure, myocardial infarction, unstable angina, 
arrhythmia, or stroke); CV (cardiovascular events); and non-CV 
(noncardiovascular events). Black circles and lines represent 
unadjusted HR and 95% CI. Gray squares and lines represent 
HR and 95% CI adjusted for age, obesity, New York Heart Asso-
ciation status, heart failure (HF) cause, HF hospitalization within 6 
months, comorbidities/risk factors (history of hypertension, stable 
angina pectoris, myocardial infarction, percutaneous coronary 
intervention/coronary artery bypass surgery, atrial fibrillation, dia-
betes mellitus, stroke/transient ischemic attack, chronic obstruc-
tive lung disease, valve disease, smoking), ejection fraction, heart 
rate, systolic blood pressure, hemoglobin, N-terminal pro-B-type 
natriuretic peptide, neutrophil count, glomerular filtration rate, 
and medications.
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difference in risk of all-cause events was modified by atrial 
fibrillation, stable angina pectoris, NYHA class, and renal 
function.
Prior reports from HF trials that examined sex differ-
ences were largely limited to HF with reduced ejection 
fraction and included relatively small numbers of women.13 
I-PRESERVE is the largest prospective trial of HFPEF to 
date and the first in which the majority of patients were 
women, reflecting its prevalence in the population. The 
number of women in I-PRESERVE (n=2491) was more 
than twice that of CHARM-Preserved, the largest previ-
ously reported trial of HFPEF. Furthermore, the baseline 
characteristics of the I-PRESERVE patients closely resem-
bled those with HFPEF described in population-based 
studies.1,2 In contrast, in CHARM-Preserved there was a 
dominance of men, coronary artery disease, and relatively 
low mean ejection fraction in patients who were, on aver-
age, younger than those seen in population and community 
studies. This was also the case for the report from the ear-
lier DIG [Digitalis Intervention Group] trial.14
These are important considerations because age, sex, 
comorbidities, and outcomes are closely related in HF: 
women with HF tend to be older than men with HF, lead-
ing to the speculation that women with HFPEF, being older, 
would have more noncardiovascular comorbidities, thus pre-
disposing them to a higher rate of noncardiovascular events 
than men.21 Our findings are contrary to this hypothesis. 
In this sample, the age distributions were similar between 
women and men with HFPEF, and the risk of noncardiovas-
cular events was lower in women, even when adjustments 
were made for several significant sex differences in the 
baseline characteristics. It is notable that noncardiovascular 
events were common (although cardiovascular events pre-
dominated), with ≈30% of all deaths and 45% of hospital-
izations because of noncardiovascular causes. These rates 
of noncardiovascular outcomes are similar to those reported 
from population-based studies and Medicare claims data of 
HFPEF21–26 and far exceed the rates of noncardiovascular 
events typically seen in patients with HF with reduced ejec-
tion fraction where men predominate.27
Table 3. Total Mortality and Hospitalizations and Causes in Women and Men
Events
Numbers (%) of Events* Event Rate Per 100 Patient-Years of Follow-Up†
Women (n=2491) Men (n=1637) Women Men Risk Ratio (95% CI) P Value
Deaths
 All-cause deaths 447 434 4.32 6.72 0.64 (0.56–0.74) <0.0001
  Noncardiovascular deaths 130 (29.1) 138 (31.8) 1.26 2.14 0.59 (0.46–0.75) <0.0001
  Cardiovascular deaths 260 (58.2) 272 (62.7) 2.51 4.21 0.60 (0.50–0.71) <0.0001
    Sudden death 104 (23.3) 127 (29.3) 1.01 1.97 0.51 (0.39–0.67) <0.0001
Pump failure 62 (13.9) 63 (14.5) 0.6 0.98 0.61 (0.43–0.89) 0.007
Stroke 45 (10.1) 31 (7.1) 0.44 0.48 0.91 (0.56–1.48) 0.67
Myocardial infarction 23 (5.1) 22 (5.1) 0.22 0.34 0.65 (0.34–1.23) 0.16
Other vascular death 17 (3.8) 15 (3.5) 0.16 0.23 0.70 (0.33–1.52) 0.33
Other cardiac death 9 (2.0) 14 (3.2) 0.09 0.22 0.40 (0.15–0.99) 0.033
  Unknown/unclassified deaths 57 (12.8) 24 (5.5) 0.55 0.37 1.48 (0.91–2.50) 0.1
Hospitalizations
 All-cause hospitalizations 3239 2537 31.33 39.29 0.80 (0.76–0.84) <0.0001
  Noncardiovascular hospitalizations 1462 (45.1) 1130 (44.5) 14.1 17.5 0.81 (0.75–0.87) <0.0001
  Cardiovascular hospitalizations 1761 (54.4) 1407 (55.5) 17.0 21.8 0.78 (0.73–0.86) <0.0001
Worsening heart failure 736 (22.7) 506 (19.9) 7.1 7.8 0.91 (0.81–1.02) 0.098
  Cardiovascular procedure 147 (4.5) 182 (7.2) 1.42 2.81 0.50 (0.40–0.63) <0.0001
  Unstable angina/MI 196 (6.1) 162 (6.4) 1.90 2.50 0.76 (0.61–0.94) 0.009
  Arrhythmia 166 (5.1) 117 (4.6) 1.61 1.81 0.89 (0.70–1.13) 0.32
  Chest pain 131 (4.0) 122 (4.8) 1.27 1.89 0.67 (0.52–0.87) 0.002
  Stroke/transient ischemic attack 126 (3.9) 105 (4.1) 1.22 1.63 0.75 (0.57–0.98) 0.03
  Other cardiac 79 (2.4) 53 (2.1) 0.76 0.82 0.93 (0.65–1.34) 0.68
  Peripheral vascular disease 59 (1.8) 57 (2.2) 0.57 0.88 0.65 (0.44–0.95) 0.02
  Syncope 42 (1.3) 61 (2.4) 0.41 0.94 0.43 (0.28–0.65) <0.0001
  Hypertension 58 (1.8) 16 (0.6) 0.56 0.25 2.26 (1.28–4.22) 0.002
  Hypotension 19 (0.6) 19 (0.7) 0.18 0.29 0.62 (0.31–1.25) 0.15
  Sudden death 2 (0.1) 1 (<0.1) 0.02 0.015 1.25 (0.07–73.7) 0.9
MI indicates myocardial infarction.
*Numbers represent absolute numbers of events (% of total events in women and men), including multiple hospitalizations per patient.
†Numbers represent rates of death and first admission to hospital for specified causes per 100 patient-years of follow-up.
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Our analyses of I-PRESERVE data indicate that among 
elderly patients with HFPEF, women, in general, had a lower 
risk of adverse clinical events than men. These results are 
consistent with previous reports, including the recently pub-
lished Meta-Analysis Global Group In Chronic Heart Failure 
(MAGGIC) meta-analysis,28 where women with HF were 
shown to have lower all-cause mortality over 3 years than 
men, irrespective of ejection fraction and even after account-
ing for baseline differences in risk factors. Similarly, in the 
overall CHARM program, first cardiovascular events were 
lower in women than men, regardless of ejection fraction. 
However, our results differ from CHARM because all-cause 
and noncardiovascular hospitalization risks for women were 
also lower than in men in our cohort. Sex-specific data in 
HFPEF alone from CHARM-Preserved were displayed but 
were not analyzed in depth,29 and the estimated sex-specific 
event rates did not seem to be lower in women. Of note, unlike 
in CHARM-Preserved, we used the composite end point of 
death or hospitalization. We, therefore, extend the previously 
published data by showing that lower risk with typical HFPEF 
persisted in women than men using composite outcomes for 
mortality, as well as hospitalizations, and was observed not 
only for first events but also for multiple all-cause, cardiovas-
cular, and noncardiovascular events experienced throughout 
the entire 49-month period of follow-up.
We further examined whether the relative risk in women 
versus men depended on the values of specific baseline 
characteristics. Atrial fibrillation and renal dysfunction 
seemed to carry greater risk in women than men. Previous 
studies have shown that women are more likely than men 
to experience symptomatic episodes of atrial fibrillation, 
higher heart rates during episodes, and a higher frequency 
of recurrences.30 Although further research is needed to 
understand these sex differences in risk, potential reasons 
may include the lower rate of treatment with statins31 or the 
higher rate of obesity among women compared with men in 
our cohort, both of which may predispose women to more 
severe arrhythmic episodes (though not necessarily greater 
prevalence of disease). The coexistence of renal dysfunction 
in HFPEF is common but poorly understood and often under-
diagnosed.32 Despite recognition of renal dysfunction as an 
important predictor of outcomes in HFPEF among women,33 
the sex difference in the extent of risk imparted by similar 
degrees of renal dysfunction has not been widely appreciated 
previously. The differential impact of symptoms of angina 
and HF on women versus men may relate to known difficul-
ties of interpreting symptoms of ischemic heart disease in 
women, which are more often atypical in women than men, 
or differences in perception of symptoms between women 
and men. Although these data extend previous reports, we 
agree with other commentators28 that there remains uncer-
tainty regarding the interaction between HF cause and sex-
related outcomes, as well as the need for further studies to 
understand this relationship.
Table 4. Sex Differences in the Multivariable Predictors of All-Cause Events
Variable
HR (95% CI); P  Value P  Value
InteractionWomen Men
Age 1.024 (1.014–1.035); <0.001 1.025 (1.013–1.037); <0.001 0.45
Obesity 1.210 (1.063–1.377); 0.004 1.136 (0.969–1.330); 0.115 0.52
NYHA (class III/IV vs I/II) 1.019 (0.852–1.220); 0.835 1.329 (1.076–1.640); 0.008 0.006
HF cause (ischemic vs nonischemic) 1.046 (0.868–1.262); 0.635 1.159 (0.956–1.406); 0.134 0.054
Hypertension 0.845 (0.677–1.055); 0.138 0.999 (0.813–1.228); 0.990 0.41
Stable angina pectoris 1.020 (0.880–1.182); 0.795 1.117 (0.947–1.317); 0.191 0.007
Myocardial infarction 1.035 (0.859–1.247); 0.718 1.040 (0.867–1.248); 0.669 0.13
PCI/CABG 1.107 (0.870–1.408); 0.408 1.242 (1.011–1.525); 0.039 0.96
Atrial fibrillation 1.115 (0.928–1.341); 0.244 0.834 (0.680–1.022); 0.080 0.005
Diabetes mellitus 1.454 (1.128–1.872); 0.004 1.178 (0.851–1.631); 0.323 0.49
Smoking 1.117 (0.905–1.378); 0.301 1.208 (1.035–1.410); 0.016 0.58
Chronic obstructive lung disease 1.351 (1.081–1.689); 0.008 1.301 (1.054–1.606); 0.014 0.59
Valve disease 1.117 (0.925–1.349); 0.248 1.140 (0.909–1.431); 0.257 0.47
Heart rate (per 1 bpm) 1.004 (0.998–1.010); 0.247 1.004 (0.996–1.011); 0.336 0.97
SBP (per 1 mm Hg) 1.000 (0.996–1.005); 0.889 1.000 (0.995–1.005); 0.917 0.90
Hemoglobin (per 1 g/dL) 0.962 (0.929–0.996); 0.029 0.946 (0.912–0.982); 0.003 0.95
NT-pro-BNP (per 1 log unit) 1.172 (1.085–1.265); <0.001 1.174 (1.077–1.281); ≤0.001 0.44
Hospitalization in 6 mo 1.447 (1.240–1.690); <0.001 1.411 (1.171–1.700); <0.001 0.049
Neutrophil count (per 1 log unit) 1.154 (0.966–1.377); 0.114 1.634 (1.309–2.041); <0.001 0.048
Ejection fraction 0.985 (0.972–0.999); 0.033 0.992 (0.977–1.007); 0.281 0.70
eGFR (per 1 mL/min per 1.73 m2) 0.991 (0.987–0.994); <0.001 0.997 (0.993–1.002); 0.211 0.01
Antiarrythmic 1.320 (1.052–1.656); 0.016 1.036 (0.806–1.333): 0.781 0.004
HR indicates hazards ratio; NYHA, New York Heart Association; HF, heart failure; PCI/CABG, percutaneous coronary intervention/coronary artery bypass surgery; bpm, 
beats per minute; SBP, systolic blood pressure; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; eGFR, estimated glomerular filtration rate.
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Limitations
Our study was performed in the context of a clinical trial, 
which may limit the generalizability of our findings. How-
ever, the I-PRESERVE cohort at baseline closely resembled 
the patients with typical HFPEF described in population-
based epidemiological studies.1,2 Furthermore, I-PRESERVE 
had the largest group of women with HFPEF in a prospective 
study of HFPEF and included detailed characterization, sys-
tematic long-term follow-up, and adjudication of outcomes. 
As in all studies, we cannot definitively exclude that some 
of the outcomes that seemed to be sex related were instead 
because of other unmeasured factors or chance, given the 
number of comparisons. Thus, these results should be inter-
preted with caution and confirmed in future studies.
Conclusion
There were several sex differences in elderly patients with 
typical HFPEF in I-PRESERVE. Women had better overall 
prognosis than men and were at lower risk of both cardiovas-
cular and noncardiovascular events, although this effect was 
modified by the presence or absence of atrial fibrillation, renal 
dysfunction, stable angina pectoris, or advanced NYHA class 
symptoms. Further research is needed to understand the com-
plex sex-related differences in risk among patients with HF. 
A better understanding of sex-specific risk factors may help 
inform strategies aimed at improving outcomes in this impor-
tant disorder.
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Epidemiological studies have revealed sex-related differences in clinical presentation, risk factors, and prognosis of heart 
failure (HF). One of the most notable sex-related differences in HF is that most women have HF with preserved ejection frac-
tion (HFPEF). However, there are few sex-specific outcome data for HFPEF. We assessed sex differences in baseline charac-
teristics and outcomes among 4128 patients with HFPEF in the Irbesartan in Heart Failure with Preserved Ejection Fraction 
(I-PRESERVE) trial. There were notable sex-related differences in baseline risk factors. Women were more likely to be 
obese and have a history of hypertension or renal impairment and were only ≈1 year older than men. Men were more likely to 
have an ischemic cause for HFPEF, atrial fibrillation, chronic obstructive pulmonary disease, and anemia. Even accounting 
for these baseline differences, women with HFPEF were ≈20% less likely than men to experience death or hospitalization for 
any cause during follow-up. A lower risk was observed in women for both cardiovascular and noncardiovascular events. This 
lower relative risk for women could not be explained by adjustment for differences in baseline characteristics. However, the 
sex-related difference in risk of all-cause events was modified by atrial fibrillation, stable angina pectoris, New York Heart 
Association functional class, and renal function. A better understanding of sex-specific risk factors may help inform strate-
gies aimed at improving outcomes in this important disorder.
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